Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Title:
Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study
Author:
Cho, Byoung Chul Abreu, Delvys Rodriguez Hussein, Maen Cobo, Manuel Patel, Anjan J Secen, Nevena Lee, Ki Hyeong Massuti, Bartomeu Hiret, Sandrine Yang, James Chih Hsin Barlesi, Fabrice Lee, Dae Ho Ares, Luis Paz Hsieh, Robert W Patil, Namrata S Twomey, Patrick Yang, Xiaoying Meng, Raymond Johnson, Melissa L